Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

A number of other equities analysts also recently weighed in on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research note on Thursday, November 14th. Chardan Capital reaffirmed a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Seres Therapeutics presently has an average rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Price Performance

MCRB stock traded down $0.01 during trading on Tuesday, reaching $0.78. The company had a trading volume of 698,501 shares, compared to its average volume of 1,581,978. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $1.53. The company has a market cap of $132.61 million, a P/E ratio of -3.38 and a beta of 2.11. The business has a 50 day moving average of $0.84 and a 200 day moving average of $0.85.

Institutional Investors Weigh In On Seres Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in MCRB. Millennium Management LLC increased its position in shares of Seres Therapeutics by 77.2% during the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after acquiring an additional 788,762 shares in the last quarter. Vontobel Holding Ltd. boosted its holdings in Seres Therapeutics by 137.6% in the fourth quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock worth $780,000 after purchasing an additional 543,469 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Seres Therapeutics by 22.5% in the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after purchasing an additional 255,014 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Seres Therapeutics by 42.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after purchasing an additional 222,771 shares during the last quarter. Finally, FMR LLC boosted its holdings in Seres Therapeutics by 0.6% in the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after purchasing an additional 140,096 shares during the last quarter. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.